Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization

Archives of Ophthalmology

Volumn 126, Issue 6, 2008, Pages 782-790

  Tatar, Olcay ^a   Yoeruek, Efdal ^a   Szurman, Peter ^a   Bartz Schmidt, Karl Ulrich ^a   Adam, Annemarie ^b   Shinoda, Kei ^e   Eckardt, Claus ^c   Boeyden, Vicky ^f   Claes, Carl ^f   Pertile, Grazia ^g   Scharioth, Gabor B ^d   Grisanti, Salvatore ^a,h  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Augenklinik der Staedtischen Kliniken   (Germany)

^d Augenzentrum Recklinghausen   (Germany)

^e National Hospital Organization   (Japan)

^f SINT AUGUSTINUS HOSPITAL   (Belgium)

^g SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^h UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD45 ANTIGEN; CD68 ANTIGEN; CYTOKERATIN 18; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; PEGAPTANIB; RANIBIZUMAB; THY 1 ANTIGEN; TRIAMCINOLONE ACETONIDE;

AGED; BRUCH MEMBRANE; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEUKOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; STROMA; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CHOROIDAL NEOVASCULARIZATION; ENDOSTATINS; FEMALE; HUMANS; IMMUNOLOGIC TECHNIQUES; INFLAMMATION; LEUKOCYTES; MACROPHAGES; MALE; MIDDLE AGED; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; STAINING AND LABELING; TISSUE DISTRIBUTION;

EID: 45149087968     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.6.782     Document Type: Review

References (83)

1. Hyman L. Epidemiology of eye disease in the elderly. Eye. 1987;1(pt 2):330-341.
2. Bressler NM, Bressler SB, Fine SL. Age related macular degeneration. Surv Ophthalmol. 1988;32(6):375-413.
3. Guyer DR, Fine SL, Maguire MG, et al. Subfoveal choroidal neovascular membranes in age related macular degeneration: visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol. 1986;104(5):702-705.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
5. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
6. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
8. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study [published online ahead of print October 5, 2006]. Ophthalmology. 2006;113(11):2002.e1-2002.e12.
9. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [published online ahead of print February 3, 2006]. Ophthalmology. 2006;113(3):363.e5-372.e5.
10. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383-390.
11. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26(9):988-993.
12. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119-126.
13. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40(9):1891-1898.
14. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992;114(4):464-472.
15. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells [published online ahead of print December 6, 2000]. J Biol Chem. 2001;276(10):7614-7620.
16. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocytes adhesion in vivo. Am J Pathol. 2002;160(2):501-509.
17. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172(6):1535-1545.
18. Lee WS, Jain MK, Arkonac BM, et al. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. Circ Res. 1998;82(8):845-851.
19. Marneros AG, She H, Zambarakji H, et al. Endogenous endostatin inhibits choroidal neovascularization [published online ahead of print May 25, 2007]. FASEB J. 2007;21(14):3809-3818.
20. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol. 1994;55(3):410-422.
21. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000;486(3):247-251.
22. Karak AK, Sarkar C, Chumber S, Tandon N. MIB-1 proliferative index in parathyroid adenoma and hyperplasia. Indian J Med Res. 1997;105:235-238.
23. Bressler NM, Bressler SB, Childs AL, et al; Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings SST report No. 13. Ophthalmology. 2004;111(11):1993-2006.
24. Wong D, Stanga P, Briggs M, et al. Case selection in macular relocation surgery for age related macular degeneration. Br J Ophthalmol. 2004;88(2):186-190.
25. Gelisken F, Karim-Zoda K, Grisanti S, Bartz-Schmidt KU. Macular translocation with 360 degrees retinotomy for retinal pigment epithelial tear. Graefes Arch Clin Exp Ophthalmol. 2005;243(6):619-621.
26. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology. 2004;111(9):1715-1724.
27. Aisenbrey S, Lafaut BA, Szurman P, et al. Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol. 2002;120(4):451-459.
28. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol. 1999;117(10):1329-1345.
29. Bressler NM, Bressler SB, Childs AL, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol. 2001;119(2):198-207.
30. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26(3):352-354.
31. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26(3):354-356.
32. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275-278.
33. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26(6):699-700.
34. Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol. 2006;124(6):815-823.
35. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81(2):154-162.
36. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration [published online ahead of print July 12, 2005]. Exp Eye Res. 2006;82(1):99-110.
37. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol. 2005;167(5):1451-1459.
38. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization [published online ahead of print February 1, 2006]. Proc Natl Acad Sci U S A. 2006;103(7):2328-2333.
39. Ambati J, Anand A, Fernandez S, et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice [published online ahead of print October 19, 2003]. Nat Med. 2003;9(11):1390-1397.
40. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87(8):3336-3343.
41. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol. 1994;232(6):325-329.
42. Nishimura T, Goodnight R, Prendergast RA, Ryan SJ. Activated macrophages in experimental subretinal neovascularization. Ophthalmologica. 1990;200(1):39-44.
43. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature. 1987;329(6140):630-632.
44. Pavilack MA, Elner VM, Elner SG, Todd RF III, Huber AR. Differential expression of human corneal and perilimbal ICAM-1 by inflammatory cytokines. Invest Ophthalmol Vis Sci. 1992;33(3):564-573.
45. Elner SG, Elner VM, Pavilack MA, et al. Modulation and function of intercellular adhesion molecule-1 (CD54) on human retinal pigment epithelial cells. Lab Invest. 1992;66(2):200-211.
46. Platts KE, Benson MT, Rennie IG, Sharrard RM, Rees RC. Cytokine modulation of adhesion molecule expression on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1995;36(11):2262-2269.
47. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
48. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(8):3578-3585.
49. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(8):3586-3592.
50. Kwak N, Okamoto N, Wood J, et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(10):3158-3164.
51. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immuno-reactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855-868.
52. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-346.
53. Higgins GT, Wang JH, Dockery P, Cleary PE, Redmond HP. Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments. Invest Ophthalmol Vis Sci. 2003;44(4):1775-1782.
54. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol Med. 2004;10(9):417-420.
55. Bora NS, Kaliappan S, Jha P, et al. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol. 2007;178(3):1783-1790.
56. Sakurai E, Taguchi H, Anand A, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(6):2743-2749.
57. Shi X, Semkova I, Muther PS, Dell S, Kociok N, Joussen AM. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization [published online ahead of print September 7, 2006]. Exp Eye Res. 2006;83(6):1325-1334.
58. Sakurai E, Noziak M, Raisler BJ, et al. Inhibition of choroidal neovascularization by VEGF - a blockade is mediated via Ccl-2 suppression [ARVO E-abstract]. Invest Ophthalmol Vis Sci. 2005;46:E-abstract 3027.
59. Tsuchihashi S, Ke B, Kaldas F, et al. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol. 2006;168(2):695-705.
60. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26(3):262-269.
61. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024-1028.
62. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling [published online ahead of print September 19, 2005]. Am J Physiol Heart Circ Physiol. 2006;290(2):H547-H559.
63. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature [published online ahead of print September 19, 2005]. Am J Physiol Heart Circ Physiol. 2006;290(2):H560-H576.
64. Meeson AP, Argilla M, Ko K, Witte L, Lang RA. VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development. 1999;126(7):1407-1415.
65. Lobov IB, Rao S, Carroll TJ, et al. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature. 2005;437(7057):417-421.
66. Chavakis T, Cines DB, Rhee JS, et al. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis [published online ahead of print June 19, 2004]. FASEB J. 2004;18(11):1306-1308.
67. Lang RA. Apoptosis in mammalian eye development: lens morphogenesis, vascular regression and immune privilege. Cell Death Differ. 1997;4(1):12-20.
68. Diez-Roux G, Argilla M, Makarenkova H, Ko K, Lang RA. Macrophages kill capillary cells in G1 phase of the cell cycle during programmed vascular regression. Development. 1999;126(10):2141-2147.
69. Diez-Roux G, Lang RA. Macrophages induce apoptosis in normal cells in vivo. Development. 1997;124(18):3633-3638.
70. Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 2006;3(8):e310.
71. Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with agerelated macular degeneration. Invest Ophthalmol Vis Sci. 2004;45(5):1544-1552.
72. Li W, He Z, Li Y, Yanoff M. Vascular endothelial growth factor regulates both apoptosis and angiogenesis of choriocapillaris endothelial cells. Microvasc Res. 2000;59(2):286-289.
73. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306-1309.
74. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol. 1995;164(2):385-394.
75. Hoffmann S, Masood R, Zhang Y, et al. Selective killing of RPE with a vascular endothelial growth factor chimeric toxin. Invest Ophthalmol Vis Sci. 2000;41(8):2389-2393.
76. Zubilewicz A, Hecquet C, Jeanny JC, Soubrane G, Courtois Y, Mascarelli F. Two distinct signaling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene. 2001;20(12):1403-1413.
77. Geisen P, McColm JR, Hartnett ME. Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Exp Eye Res. 2006;82(4):608-619.
78. Peters S, Julien S, Heiduschka P, et al; Tuebingen Bevacizumab Study Group. Anti-permeability and anti-proliferative effects of standard and frozen bevacizumab on choroidal endothelial cells [published online ahead of print December 19, 2006]. Br J Ophthalmol. 2007;91(6):827-831.
79. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al; Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells [published online ahead of print May 24, 2006]. Br J Ophthalmol. 2006;90(10):1316-1321.
80. Tatar O, Shinoda K, Adam A, et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration [published online ahead of print April 11, 2006]. Exp Eye Res. 2006;83(2):329-338.
81. Arroyo JG. Towards a rational approach to combination therapy for neovascular age-related macular degeneration. Br J Ophthalmol. 2007;91(2):130-131.
82. Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol. 2007;7:10.
83. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27(2):133-140.